Trillium Therapeutics (TRIL) News Today → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free TRIL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.combusinesswire.com - November 10 at 1:22 PMMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 8 at 1:30 AMThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast perioduk.finance.yahoo.com - July 31 at 9:03 AMWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'msn.com - April 26 at 12:18 AMLeukemia Therapeutics Global Market Report 2023uk.finance.yahoo.com - April 4 at 10:35 AMRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merckfinance.yahoo.com - March 28 at 9:12 AMFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinomanz.finance.yahoo.com - October 19 at 9:39 AMCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatmentseekingalpha.com - September 14 at 9:48 AMZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directorsnz.finance.yahoo.com - September 12 at 7:55 AMPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Neededseekingalpha.com - August 17 at 11:07 AM10 Psychedelics CEOs To Pay Attention To In 2022markets.businessinsider.com - June 22 at 10:08 AMPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?edition.cnn.com - May 20 at 2:06 PM3 Dividend Stocks That We'd Buy Without Any Hesitationnasdaq.com - March 20 at 9:49 AMMindset Pharma CEO, James Lanthier, Issues Letter to Shareholdersstockhouse.com - March 17 at 4:24 PMNeonMind Biosciences Inc.: NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, Ontariofinanznachrichten.de - February 17 at 8:00 AMCD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 - ResearchAndMarkets.comau.finance.yahoo.com - December 14 at 6:59 PM3 Firms Draw Up Pfizer's $6.7B Arena Pharmaceuticals Buylaw360.com - December 14 at 6:59 PMTrillium Therapeutics (NASDAQ:TRIL) Lifted to "Buy" at Zacks Investment Researchmarketbeat.com - November 17 at 8:59 AMTrillium Therapeutics (NASDAQ:TRIL) Downgraded to "Hold" at Benchmarkmarketbeat.com - November 17 at 7:16 AMmarketbeat.com - November 17 at 6:05 AMIs Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?finance.yahoo.com - October 25 at 12:58 PMTrillium Therapeutics (NASDAQ:TRIL) Upgraded to "Buy" at Zacks Investment Researchmarketbeat.com - October 19 at 9:36 AM2 Top Healthcare Stocks That Could Be Bought Out in 2022msn.com - October 16 at 7:16 AMBRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14msn.com - October 13 at 10:08 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the Firmfinance.yahoo.com - September 22 at 8:16 PMSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRILfinance.yahoo.com - September 11 at 6:41 AMMoore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law Firmbenzinga.com - September 9 at 11:57 AMSHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and SIC Shareholders About Its Ongoing Investigationsfinance.yahoo.com - September 7 at 8:07 AMWhy Investors Should Love Pfizer's Acquisition of Trilliumfinance.yahoo.com - September 4 at 6:30 AMAugust M&A roundup: Trillium's redemption and Reebok's $2.5B salebizjournals.com - September 1 at 3:34 PMForget Trillium Therapeutics Stock (TSX:TRIL): Buy These Pharma Stocks Instead!ca.finance.yahoo.com - August 31 at 1:34 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Trillium Therapeutics, Inc. Buyoutfinance.yahoo.com - August 24 at 12:50 PMTrillium Therapeutics (NASDAQ:TRIL) Downgraded by JMP Securities to "Market Perform"marketbeat.com - August 24 at 7:26 AMTRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium Therapeutics Inc. - TRILfinance.yahoo.com - August 23 at 8:28 PMChip shortage to worsen, Trillium pops 180% after Pfizer buyout, Coinbase reassures on stablecoinsfinance.yahoo.com - August 23 at 3:28 PMTrillium Therapeutics shares soar on Pfizer’s $2.26B dealmsn.com - August 23 at 9:29 AMPfizer To Buy Trillium Therapeutics For $18.50/Shr Cash - Quick Factsnasdaq.com - August 23 at 9:29 AMTrillium Therapeutics soars 200% after Pfizer inks deal to buy cancer-drug company for $2.3 billionmsn.com - August 23 at 9:29 AMPfizer to buy cancer drug developer Trillium in $2.3 billion dealfinance.yahoo.com - August 23 at 9:29 AMTrillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billionfinance.yahoo.com - August 23 at 9:29 AMUPDATE 2-Pfizer to buy cancer drug developer Trillium in $2.3 bln dealfinance.yahoo.com - August 23 at 9:29 AMTrillium Therapeutics Reports Second Quarter 2021 Operating and Financial Resultsfinance.yahoo.com - August 13 at 7:12 AMTrillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemiafinance.yahoo.com - August 9 at 7:27 AM Get Trillium Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter. Email Address Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai... Get all the info here >>> TRIL Media Mentions By Week TRIL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRIL News Sentiment▼0.000.46▲Average Medical News Sentiment TRIL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRIL Articles This Week▼00▲TRIL Articles Average Week Get Trillium Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PTC Therapeutics News Galapagos News Geron News Avidity Biosciences News Amphastar Pharmaceuticals News Catalyst Pharmaceuticals News Maravai LifeSciences News Syndax Pharmaceuticals News Schrödinger News Keros Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRIL) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
